


Serial No. 09/890,741

In the Claims

Please amend the Claims as set forth below in the complete listing of Claims according to the Revised Amendment Format:

1. (Original) A compound of formula I:



I;

or a pharmaceutical acid addition salt thereof, where;

A is hydrogen, halo, $-OR^4$, NH_2 , or $-CF_3$;

R is hydrogen, C_1-C_4 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, or $(C_1-C_6$ alkyl)- Ar^1 ;

R^1 is $-NH-R^2-R^3$, hydroxy, $-OSO_2Ar^2$, or NH_2 ;

Ar , Ar^1 , Ar^2 , Ar^3 , and Ar^4 are an optionally substituted phenyl or optionally substituted heteroaryl;

R^2 is $-CO-$, $-CS-$, or $-SO_2-$;

R^3 is hydrogen, optionally substituted C_1-C_6 alkyl, Ar^3 , $-NR^5R^6$, or OR^5 ; provided R^3 is not hydrogen if R^2 is either $-CS-$ or $-SO_2-$;

R^4 is hydrogen, optionally substituted C_1-C_6 alkyl, or Ar ; and

R^5 and R^6 are independently hydrogen, optionally substituted C_1-C_8 alkyl, or Ar^4 ; or R^5 and R^6 combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

2. (Original) The compound of Claim 1 wherein A is hydrogen.

3. (Previously Amended) The compound of Claim 1 wherein R is methyl.

4. (Previously Amended) The compound of Claim 1 wherein R^1 is $NH-R^2-R^3$.

5. (Previously Amended) The compound of Claim 4 wherein R^2 is $C=O$.

Serial No. 09/890,741


6. (Previously Amended) The compound of Claim 5 wherein R^3 is Ar^3 .

7. (Previously Amended) The compound of Claim 6 wherein Ar^3 is 4-fluorophenyl.

8. (Previously Amended) The compound of Claim 7 wherein Ar^3 is 4-fluorophenyl additionally mono- or disubstituted.

9. (Previously Amended) The compound of Claim 8 wherein Ar^3 is selected from the group consisting of 2-iodo-4-fluorophenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-difluorophenyl, and 2-methyl-4-fluorophenyl.

10. (Original) A pharmaceutical formulation comprising a compound of formula I:



I;

where;

A is hydrogen, halo, $-\text{OR}^4$, NH_2 , or $-\text{CF}_3$;

R is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_6$ alkenyl, $\text{C}_3\text{-C}_6$ alkynyl, or $(\text{C}_1\text{-C}_6$ alkyl)- Ar^1 ;

R^1 is $-\text{NH}-\text{R}^2-\text{R}^3$, hydroxy, $-\text{OSO}_2\text{Ar}^2$, or NH_2 ;

Ar , Ar^1 , Ar^2 , Ar^3 , and Ar^4 are an optionally substituted phenyl or optionally substituted heteroaryl;

R^2 is $-\text{CO}-$, $-\text{CS}-$, or $-\text{SO}_2-$;

R^3 is hydrogen, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, Ar^3 , $-\text{NR}^5\text{R}^6$, or OR^5 ; provided R^3 is not hydrogen if R^2 is either $-\text{CS}-$ or $-\text{SO}_2-$;

R^4 is hydrogen, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, or Ar ; and

R^5 and R^6 are independently hydrogen, optionally substituted $\text{C}_1\text{-C}_8$ alkyl, or Ar^4 ; or R^5 and R^6 combine, together with the nitrogen atom to

Serial No. 09/890,741

which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring;


or a pharmaceutical acid addition salt thereof, and a pharmaceutical carrier, diluent, or excipient.

✓ 11. (Cancelled)

✓ 12. (Cancelled)

✓ 13. (Cancelled)

14. (Original) A process of making the compounds of formula I(a):



wherein R³ is hydrogen, optionally substituted C₁-C₆ alkyl, Ar³, -NR⁵R⁶, or OR⁵;

R⁵ and R⁶ are independently hydrogen, optionally substituted C₁-C₈ alkyl, or Ar⁴; or R⁵ and R⁶ combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring; and

Ar³ and Ar⁴ are independently an optionally substituted phenyl or optionally substituted heteroaryl, comprising:

- (a) protecting 4-benzoylpiperidine hydrochloride to form an N-protected 4-benzoylpiperidine hydrochloride;
- (b) nitrating the N-protected 4-benzoylpiperidine hydrochloride to form a mixture of N-protected 4-(mono-nitrobenzoyl)piperidines;
- (c) deprotecting the N-protected 4-(mononitrobenzoyl)- piperidine mixture to form a mixture of 4-(mononitrobenzoyl)piperidines;
- (d) separating the 4-(3-nitrobenzoyl)piperidine from the mixture of 4-(mononitrobenzoyl)piperidines;
- (e) reducing the 4-(3-nitrobenzoyl)piperidine to form 4-(3-aminobenzoyl)piperidine; and
- (f) acylating the 4-(3-aminobenzoyl)piperidine.

Serial No. 09/890,741

15. (Original) The process of Claim 14 wherein steps a) and b) are combined.

16. (Previously amended) The process of Claim 14 wherein the source of the protecting group of step a) is trifluoroacetic anhydride.


17. (Previously amended) The process of Claim 14 wherein the source of the nitronium ion is ammonium nitrate.

B1

18. (Currently amended) The process of any of Claim 16 wherein the source of the nitronium ion is ammonium nitrate.

19. (Cancelled)

20. (Previously added) A method for treating migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I:



I;

or a pharmaceutical acid addition salt thereof, where,

A is hydrogen, halo, -OR⁴, NH₂, or -CF₃;

R is hydrogen, C₁-C₄ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, or (C₁-C₆ alkyl)-Ar¹;

R¹ is -NH-R²-R³, hydroxy, -OSO₂Ar², or NH₂;

Ar, Ar¹, Ar², Ar³, and Ar⁴ are an optionally substituted phenyl or optionally substituted heteroaryl;

R² is -CO-, -CS-, or -SO₂-;

R³ is hydrogen, optionally substituted C₁-C₆ alkyl, Ar³, -NR⁵R⁶, or OR⁵; provided R³ is not hydrogen if R² is either -CS- or -SO₂-;

R⁴ is hydrogen, optionally substituted C₁-C₆ alkyl, or Ar; and

Serial No. 09/890,741

R^5 and R^6 are independently hydrogen, optionally substituted C_1-C_8 alkyl, or Ar^4 ; or R^6 and R^5 combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

21. (Previously added) The method according to Claim 20 where the mammal is a human.


22. (Previously added) The compound of Claim 5 where A is hydrogen and R is methyl.

23. (Previously added) The compound of Claim 6 where A is hydrogen and R is methyl.

24. (Previously added) The compound of Claim 7 where A is hydrogen and R is methyl.

25. (Previously added) The compound of Claim 6 where R^1 is $-NH-R^2-R^3$, R^2 is $C=O$ and R^3 is substituted halophenyl.

26. (Reinstated - formerly original Claim 11) A method for activating $5-HT_{1F}$ receptors in mammals comprising administering to a mammal in need of such activation an effective amount of a compound of formula I:



I;

or a pharmaceutical acid addition salt thereof, where;

A is hydrogen, halo, $-OR^4$, NH_2 , or $-CF_3$;

R is hydrogen, C_1-C_4 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, or (C_1-C_6 alkyl)- Ar^1 ;

R^1 is $-NH-R^2-R^3$, hydroxy, $-OSO_2Ar^2$, or NH_2 ;

Ar , Ar^1 , Ar^2 , Ar^3 , and Ar^4 are an optionally substituted phenyl or optionally substituted heteroaryl;


Serial No. 09/890,741

 R^2 is $-CO-$, $-CS-$, or $-SO_2-$; R^3 is hydrogen, optionally substituted C_1-C_6 alkyl, Ar^3 , $-NR^5R^6$, or OR^5 ; provided R^3 is not hydrogen if R^2 is either $-CS-$ or $-SO_2-$; R^4 is hydrogen, optionally substituted C_1-C_6 alkyl, or Ar ; and R^5 and R^6 are independently hydrogen, optionally substituted C_1-C_8 alkyl, or Ar^4 ; or R^5 and R^6 combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

27. (new) The method according to Claim 26 where the mammal is a human.

β3

28. (Reinstated - formerly original Claim 12) A method for inhibiting neuronal protein extravasation comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I:



I;

or a pharmaceutical acid addition salt thereof, where,

 A is hydrogen, halo, $-OR^4$, NH_2 , or $-CF_3$; R is hydrogen, C_1-C_4 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, or $(C_1-C_6$ alkyl)- Ar^1 ; R^1 is $-NH-R^2-R^3$, hydroxy, $-OSO_2Ar^2$, or NH_2 ; Ar , Ar^1 , Ar^2 , Ar^3 , and Ar^4 are an optionally substituted phenyl or optionally substituted heteroaryl; R^2 is $-CO-$, $-CS-$, or $-SO_2-$; R^3 is hydrogen, optionally substituted C_1-C_6 alkyl, Ar^3 , $-NR^5R^6$, or OR^5 ; provided R^3 is not hydrogen if R^2 is either $-CS-$ or $-SO_2-$; R^4 is hydrogen, optionally substituted C_1-C_6 alkyl, or Ar ; and

Serial No. 09/890,741

R⁵ and R⁶ are independently hydrogen, optionally substituted C₁-C₈ alkyl, or Ar⁴; or R⁶ and R⁵ combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

B3
29. (new) The method according to Claim 28 where the mammal is a human.
